ReviewTranslational gastroenterology and hepatology2022
EUS-RFA of the pancreas: where are we and future directions.
Review in Translational gastroenterology and hepatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Recent Development of Endo-hepatology.DEN open · 2027Review
- Treatment of Hepatocellular Carcinoma Using Endoscopic Ultrasound-guided Radiofrequency Ablation: A Case Series.DEN open · 2026Article
- Advances in radiofrequency ablation for pancreatic cancer.World journal of gastrointestinal oncology · 2026Review
- Endoscopic ultrasound-guided radiofrequency ablation in the treatment of pancreatic ductal adenocarcinoma: when science tries to increases hope.Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery · 2026Article
- Endoscopic ultrasound-guided radiofrequency ablation for pancreatic cystic neoplasms: a comprehensive review.Frontiers in medicine · 2026Review
- Evolving techniques in the endoscopic evaluation and management of pancreas cystic lesions.Current opinion in gastroenterology · 2025Review
- The Palliation of Unresectable Pancreatic Cancer: Evolution from Surgery to Minimally Invasive Modalities.Journal of clinical medicine · 2025Review
- Review
- Safety and Efficacy of Radiofrequency Ablation in Management of Various Pancreatic Neoplasms.Journal of clinical medicine · 2025Article
- Review
- Endoscopic Ultrasound-Guided Chemoablation of an Acinar Cell Carcinoma as a Suppressive Strategy for Unresectable Disease.ACG case reports journal · 2025Article
- Role of endoscopic ultrasound in the diagnosis and local ablative therapy of pancreatic neuroendocrine tumors.The Korean journal of internal medicine · 2025Review
- Endoscopic ultrasonography-based intratumoral and peritumoral machine learning ultrasomics model for predicting the pathological grading of pancreatic neuroendocrine tumors.BMC medical imaging · 2025Article
- Review
- Review
- Review
- Review
- The Latest Advancements in Diagnostic Role of Endosonography of Pancreatic Lesions.Journal of clinical medicine · 2023Review
- Role of Therapeutic Endoscopic Ultrasound in Management of Pancreatic Cancer: An Endoscopic Oncologist Perspective.Cancers · 2023Review
- Recent Developments in the Field of Endoscopic Ultrasound for Diagnosis, Staging, and Treatment of Pancreatic Lesions.Cancers · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Surgical resection remains the gold standard for pancreatic cancer, high-risk pancreatic neuroendocrine tumors (PNETs) and pancreatic cystic neoplasms (PCNs). However, a majority of pancreatic cancers are unresectable at the time of diagnosis. In addition, surgical resection of pancreatic lesions can be associated with morbidity and mortality. A less-invasive alternative therapeutic intervention to avoid short term and long-term adverse events is desirable, as is a minimally-invasive palliative therapy for unresectable or recurrent pancreatic cancers. Endoscopic ultrasound guided radiofrequency ablation (EUS-RFA) allows for selective tissue ablation with minimal injury to the surrounding tissue. EUS-RFA of pancreatic tumors has shown high clinical and technical success with acceptable side effects in pancreatic lesions, lymph nodes, and the celiac plexus. This paper will review the pathophysiology, available technology, safety and efficacy, and future directions of EUS-RFA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.